SS1 CAR-T

SS1 CAR-T is a chimeric antigen receptor T cell therapy engineered to target mesothelin, a cell-surface protein that is highly expressed on several solid tumor types, including mesothelioma, ovarian cancer, and pancreatic ductal adenocarcinoma. The “SS1” refers specifically to the single-chain variable fragment (scFv) derived from the SS1 antibody, which is utilized in the extracellular antigen recognition domain of the CAR. SS1 CAR-T cells recognize mesothelin on tumor cells, promoting T cell activation, proliferation, cytokine release, and cytolytic activity via CD3ζ and co-stimulatory domains (commonly 4-1BB). The use of a murine-derived SS1 scFv creates a risk for immunogenicity (anti-IgE antibody response), which can cause hypersensitivity reactions. SS1 CAR-T therapies have been investigated in early-phase clinical trials primarily for mesothelin-expressing solid tumors, demonstrating safety for multiple infusions and evidence of trafficking to tumor tissue, but generally limited and transient anti-tumor responses. A key challenge for SS1 CAR-T has been inhibition by shed soluble mesothelin in the tumor microenvironment, which can block CAR-T activity[3][6][1].

Brand names

SS1 CAR-TSS-1 CAR-TSS 1 CAR-T

Other names

SS1 CAR-TSS-1 CAR-TSS 1 CAR-TSS1-4-1BB CAR-TSS-1-4-1BB CAR-TSS 1-4-1BB CAR-TSS1 scFv CAR-TSS-1 scFv CAR-TSS 1 scFv CAR-T